GlassScriptPhysician profile
Michael Brandon Lipp
NPI 1629483516
$2,372.76
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,923 · 2020: $93.66 · 2021: $19.48 · 2022: $92.39 · 2023: $86.23 · 2024: $158.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $244.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $244.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo Pharmaceuticals INC. | $642.92 | 2019 | |
| Abbvie INC. | $488.33 | 2019 | |
| Galderma Laboratories, L.P. | $305.72 | 2019-2023 | |
| Allergan, INC. | $213.89 | 2019-2020 | |
| Revance Therapeutics, INC. | $158.26 | 2024 | Daxxify |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $142.89 | 2019 | |
| Lilly USA, LLC | $115.40 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $112.84 | 2019 | |
| Pfizer INC. | $107.24 | 2019 | |
| Solta Medical, A Division of Bausch Health US, LLC | $19.48 | 2021 | |
| Novartis Pharmaceuticals Corporation | $19.07 | 2019 | |
| Dusa Pharmaceuticals, INC. | $18.00 | 2019 | |
| Biofrontera INC. | $16.48 | 2019 | |
| Apyx Medical Corporation | $12.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Lipp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.